Commissioner of Food and Drugs
Executive orders directing the Commissioner of Food and Drugs · 15 in Search.
Related departments
Orders
15 shown
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs federal agencies to accelerate research, regulatory review, and patient access to psychedelic drugs (including ibogaine compounds) for treating serious mental illness and reducing suicide rates. It creates FDA priority vouchers for breakthrough-designated psychedelics, establishes Right to Try access pathways, funds state-federal collaboration through ARPA-H, mandates interagency data sharing with VA, and requires timely DEA rescheduling of approved psychedelic products.
Addressing Addiction Through the Great American Recovery Initiative
This executive order establishes the White House Great American Recovery Initiative, co-chaired by the Secretary of HHS and a Senior Advisor for Addiction Recovery, to coordinate federal response to substance use disorder. The Initiative brings together 15+ officials across cabinet departments and agencies to recommend steps for aligning federal programs, increasing treatment access, and integrating addiction services across health, criminal justice, workforce, education, and housing systems.
Increasing Medical Marijuana and Cannabidiol Research
This executive order directs the Attorney General to expedite rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act to facilitate medical research. It also directs multiple health agencies to develop research methods using real-world evidence for medical marijuana and hemp-derived CBD products, and tasks White House legislative staff with working Congress to update statutory definitions for hemp-derived cannabinoids.
Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients
This executive order directs the Administration to pursue most-favored-nation prescription drug pricing, requiring pharmaceutical manufacturers to offer U.S. patients prices comparable to other developed nations or face potential rulemaking, importation waivers, antitrust enforcement, export reviews, and FDA approval modifications. It establishes a 30-day deadline for HHS to communicate price targets to drug makers, with escalating measures if progress is not achieved.
Regulatory Relief To Promote Domestic Production of Critical Medicines
This executive order directs federal agencies to streamline regulatory and permitting processes for domestic pharmaceutical manufacturing, with specific actions by FDA, EPA, Army Corps of Engineers, and OMB. It also mandates increased inspections and fees on foreign manufacturing facilities and requires public disclosure of foreign inspection data, aiming to reduce domestic facility construction timelines from 5-10 years and shift production back to the United States.
Lowering Drug Prices by Once Again Putting Americans First
This executive order directs multiple federal agencies to take steps to lower prescription drug prices, primarily by modifying the Medicare Drug Price Negotiation Program created by the Inflation Reduction Act, promoting generic and biosimilar competition, expanding drug importation, increasing transparency in pharmacy benefit manager compensation, and conditioning health center grants on providing discounted insulin and epinephrine to low-income patients.
Establishing the President's Make America Healthy Again Commission
This executive order establishes the President's Make America Healthy Again Commission, chaired by the HHS Secretary, to combat rising chronic disease rates in America with an initial focus on childhood chronic disease. The Commission must produce an assessment within 100 days and a strategy within 180 days on causes including diet, environmental factors, medical treatments, and corporate influence, while directing multiple agencies to prioritize disease prevention, research integrity, and healthy food production.
Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
This executive order launches a whole-of-government initiative to advance U.S. biotechnology and biomanufacturing capabilities across health, climate, energy, agriculture, and national security sectors. It mandates numerous agency reports and plans with specific deadlines, establishes a Data for the Bioeconomy Initiative, creates workforce development programs with equity commitments, streamlines biotechnology regulation, strengthens biosafety and biosecurity protections, and tasks intelligence agencies with assessing foreign threats to the U.S. bioeconomy.
Promoting Competition in the American Economy
This executive order establishes a whole-of-government competition policy to combat excessive market concentration across the economy. It creates a White House Competition Council and directs dozens of specific actions by agencies including the FTC, DOJ, USDA, HHS, DOT, FCC, and others to address anti-competitive practices in labor markets, agriculture, healthcare, telecommunications, transportation, and technology.
An America-First Healthcare Plan
This executive order declares a continuation of healthcare policies emphasizing patient choice, lower costs, and quality care, with specific directives to maintain existing actions and new deadlines for price transparency and surprise billing measures. It requires HHS to work with Congress on surprise billing legislation by year-end 2020, take administrative action if legislation fails, and update Medicare.gov Hospital Compare within 180 days with hospital billing quality information.
Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States
This executive order directs federal agencies to prioritize domestic procurement of essential medicines, medical countermeasures, and their critical ingredients to reduce dependence on foreign manufacturing. It mandates supply chain vulnerability assessments, streamlines regulatory approvals for domestic producers, and authorizes use of the Defense Production Act to prioritize these materials. The order includes exceptions for public health emergencies and when domestic procurement would increase costs by more than 25 percent.
Promoting American Seafood Competitiveness and Economic Growth
This executive order directs federal agencies to reduce regulatory barriers for domestic fishing and aquaculture, combat illegal fishing, streamline permitting for offshore aquaculture projects, establish designated aquaculture zones, and develop a comprehensive seafood trade strategy. It creates multiple task forces and deadlines across Commerce, Agriculture, Army Corps of Engineers, and other agencies to expand U.S. seafood production and reduce reliance on imports.
Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health
This executive order establishes a National Influenza Vaccine Task Force co-chaired by Defense and HHS to modernize U.S. influenza vaccine production away from egg-based methods toward faster, scalable cell-based and recombinant technologies. It mandates a 5-year national plan and directs multiple agencies to estimate costs, expand manufacturing capacity, and accelerate development of broadly protective vaccines.
Modernizing the Regulatory Framework for Agricultural Biotechnology Products
This executive order directs federal agencies to modernize regulations for agricultural biotechnology products, streamline oversight across USDA, EPA, and FDA, and promote both domestic public acceptance and international trade of genetically engineered crops and animals. It mandates specific plans for regulatory streamlining, a unified web-based platform for developers, consumer engagement strategies, and international trade barrier removal.
Reducing Prescription Drug Shortages
This executive order directs the FDA to use existing authority to require earlier notice from manufacturers about drug discontinuances that could cause shortages, expedite regulatory reviews when shortages are threatened, and refer evidence of price gouging or hoarding to the Department of Justice for potential enforcement. It responds to a near-tripling of prescription drug shortages between 2005 and 2010, particularly for cancer treatments and anesthesia drugs.